Search

Your search keyword '"Abrey, L E"' showing total 100 results

Search Constraints

Start Over You searched for: Author "Abrey, L E" Remove constraint Author: "Abrey, L E" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
100 results on '"Abrey, L E"'

Search Results

6. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors

7. CLIN-MEDICAL + RADIATION THERAPIES

8. Response to Weltman and Fleury Malheiros, re Lassman et al.

9. Initial treatment patterns over time for anaplastic oligodendroglial tumors

10. MEDICAL AND NEURO-ONCOLOGY

12. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas

13. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

16. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).

17. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

19. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

20. Ongoing Clinical Trials

26. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

29. Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial

33. Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL)

36. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report

41. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

46. A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)

Catalog

Books, media, physical & digital resources